Last reviewed · How we verify
Placebo and sequential therapy — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo and sequential therapy (Placebo and sequential therapy) — National Taiwan University Hospital. Placebo and sequential therapy is a clinical trial design approach rather than a pharmacological drug, used to evaluate treatment efficacy through sequential administration of placebo followed by active therapy.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo and sequential therapy TARGET | Placebo and sequential therapy | National Taiwan University Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo and sequential therapy CI watch — RSS
- Placebo and sequential therapy CI watch — Atom
- Placebo and sequential therapy CI watch — JSON
- Placebo and sequential therapy alone — RSS
Cite this brief
Drug Landscape (2026). Placebo and sequential therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-and-sequential-therapy. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab